deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 0.66 [0.56; 0.78], 2 RCTs, I2=0%
unassessable degree of certainty